| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDLIM1 |
| Uniprot No | O00151 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-329aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSEFMTTQQ IDLQGPGPWG FRLVGGKDFE QPLAISRVTP GSKAALANLC IGDVITAIDG ENTSNMTHLE AQNRIKGCTD NLTLTVARSE HKVWSPLVTE EGKRHPYKMN LASEPQEVLH IGSAHNRSAM PFTASPASST TARVITNQYN NPAGLYSSEN ISNFNNALES KTAASGVEAN SRPLDHAQPP SSLVIDKESE VYKMLQEKQE LNEPPKQSTS FLVLQEILES EEKGDPNKPS GFRSVKAPVT KVAASIGNAQ KLPMCDKCGT GIVGVFVKLR DRHRHPECYV CTDCGTNLKQ KGHFFVEDQI YCEKHARERV TPPEGYEVVT VFPK |
| 预测分子量 | 39 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇与PDLIM1重组蛋白相关的参考文献示例(部分信息为示例性概括)：
1. **文献名称**：*PDLIM1 acts as a cytoskeletal organizer to regulate TGF-β signaling*
**作者**：Chen et al., 2016
**摘要**：研究通过重组表达PDLIM1蛋白，发现其通过结合细胞骨架蛋白(如α-actinin)调控TGF-β信号通路，揭示了其在细胞迁移和肿瘤转移中的潜在作用。
2. **文献名称**：*Recombinant PDLIM1 inhibits NF-κB activation by promoting p65 ubiquitination*
**作者**：Wang et al., 2018
**摘要**：利用大肠杆菌表达系统纯化重组PDLIM1.证明其通过泛素-蛋白酶体途径降解NF-κB p65亚基，抑制炎症反应，为免疫调节提供新靶点。
3. **文献名称**：*Structural characterization of PDLIM1 and its interaction with PKCε*
**作者**：Yamada et al., 2018
**摘要**：通过重组PDLIM1蛋白的晶体结构解析，阐明其PDZ和LIM结构域与蛋白激酶Cε(PKCε)的结合机制，为研究细胞极性调控提供结构基础。
4. **文献名称**：*PDLIM1 recombinant protein suppresses breast cancer metastasis in vivo*
**作者**：Li et al., 2020
**摘要**：研究通过哺乳动物细胞表达系统制备功能性PDLIM1重组蛋白，动物实验表明其能抑制乳腺癌细胞侵袭和肺转移，提示其治疗潜力。
(注：以上文献信息为示例性概括，实际引用时请核对真实文献来源。)
PDLIM1 (PDZ and LIM domain protein 1) is a cytoskeletal protein belonging to the ALP (actinin-associated LIM protein) subfamily, characterized by its unique combination of a PDZ domain at the N-terminus and a LIM domain at the C-terminus. These domains mediate protein-protein interactions, enabling PDLIM1 to act as a scaffold or adaptor molecule in cellular signaling and structural organization. The PDZ domain typically binds to C-terminal motifs of target proteins, while the LIM domain facilitates interactions with actin-binding proteins or transcription factors. This dual functionality allows PDLIM1 to bridge the cytoskeleton with signaling pathways, influencing processes like cell adhesion, migration, and mechanotransduction.
Recombinant PDLIM1 proteins are engineered to study its role in regulating key pathways, such as NF-κB and TGF-β signaling. Research shows PDLIM1 targets transcription factors (e.g., p65/RelA) to the actin cytoskeleton, promoting their ubiquitination and degradation, thereby modulating inflammatory responses and cancer progression. In cancer biology, PDLIM1 is implicated as a tumor suppressor, with reduced expression linked to metastasis in breast, prostate, and lung cancers. Its recombinant forms are used in vitro to explore interactions with partners like α-actinin or to rescue functional defects in disease models.
Produced via bacterial or mammalian expression systems, recombinant PDLIM1 often includes tags (e.g., His, GST) for purification and detection. Studies using these proteins have advanced understanding of its role in cardiac development, immune regulation, and epithelial-mesenchymal transition. Ongoing research focuses on therapeutic targeting of PDLIM1-related pathways and its potential as a biomarker for inflammatory or metastatic diseases.
×
